提高微生物群对癌症免疫疗法的预测价值

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-07-31 DOI:10.1016/j.trecan.2024.07.007

{"title":"提高微生物群对癌症免疫疗法的预测价值","authors":"","doi":"10.1016/j.trecan.2024.07.007","DOIUrl":null,"url":null,"abstract":"The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al.<svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg> describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"10 1","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Towards enhancing the predictive value of the microbiota for cancer immunotherapy\",\"authors\":\"\",\"doi\":\"10.1016/j.trecan.2024.07.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al.<svg aria-label=\\\"Opens in new window\\\" focusable=\\\"false\\\" height=\\\"20\\\" viewbox=\\\"0 0 8 8\\\"><path d=\\\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\\\"></path></svg> describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.07.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.07.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肠道微生物群已成为免疫检查点抑制剂（ICI）反应的潜在决定因素，但将其用作生物标志物仍具有挑战性。Derosa 等人最近在《细胞》（Cell）杂志上发表的一项研究介绍了一种基于肠道微生物群组成的双层模型，用于区分有反应和无反应的癌症患者，提供了可在临床中利用的新思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Towards enhancing the predictive value of the microbiota for cancer immunotherapy

The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.